Accuray Incorporated has announced that studies on the clinical use of the CyberKnife System continue to demonstrate its benefits across a wide range of cancer indications and stages in the cancer treatment journey. More than 50 studies were presented during poster and oral sessions at the 36th Annual European Society for Radiotherapy & Oncology (ESTRO) Meeting in Vienna, May 5-9. Some of the studies show long-term efficacy and safety with median follow-up exceeding five years.
CyberKnife stereotactic body radiation therapy (SBRT) is used worldwide for effective management of prostate cancer
The CyberKnife System provides benefits for primary cases, recurrent and metastatic diseases
Technical innovations improve the delivery of radiation therapy
The CyberKnife System was designed to deliver treatment beams of different size and shape from hundreds of non-coplanar, isocentric or non-isocentric angles around the patient, enabling the clinician to deliver high-quality treatment plans with extreme precision, sparing surrounding healthy tissue and structures. The system's tracking capabilities eliminate the need for gating techniques and restrictive head frames, providing greater comfort for the patient.
"I am proud to see that the unique capabilities of our radiation therapy delivery systems are enabling clinicians to develop innovative approaches for delivering radiation treatments which make a real difference in their patients' lives," said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. "Since 1994 when the first patient was treated with the CyberKnife System, it has set the bar for delivering precise radiation treatments while avoiding healthy tissue. The data presented at ESTRO 36 reinforce the system's benefits and show it is increasingly being used to treat a wide range of cancer cases."Back To Top
ESTRO 2017: New data reinforce CyberKnife’s versatility, precision. Appl Rad Oncol.